Literature DB >> 19148945

Exploiting apoptosis pathways for the treatment of pediatric cancers.

Simone Fulda1.   

Abstract

Resistance to apoptosis (programmed cell death) is a characteristic feature of human cancers including childhood malignancies. Further, evasion of apoptosis is a frequent cause of treatment resistance, since most anti-cancer therapies, for example chemo- or radiotherapy act primarily by inducing apoptosis in cancer cells. Over the last two decades, the dissection of apoptosis pathways in pediatric tumors has resulted in the identification of many key molecules that may serve as molecular targets for drug discovery. Accordingly, components of the apoptotic cascade are currently exploited for the development of rationally designed molecular targeted therapies. This approach is expected to open new and more effective approaches for the treatment of childhood cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148945     DOI: 10.1002/pbc.21922

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

Authors:  Melinda S Merchant; James I Geller; Kristin Baird; Alexander J Chou; Susana Galli; Ava Charles; Martha Amaoko; Eunice H Rhee; Anita Price; Leonard H Wexler; Paul A Meyers; Brigitte C Widemann; Maria Tsokos; Crystal L Mackall
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

2.  Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.

Authors:  Katja Simon-Keller; Annette Paschen; Andreas A Hombach; Philipp Ströbel; Jean-Michel Coindre; Stefan B Eichmüller; Angela Vincent; Stefan Gattenlöhner; Florian Hoppe; Ivo Leuschner; Sabine Stegmaier; Ewa Koscielniak; Martin Leverkus; Dario C Altieri; Hinrich Abken; Alexander Marx
Journal:  Am J Pathol       Date:  2013-04-02       Impact factor: 4.307

3.  Generation and characterization of antibodies specific for caspase-cleaved neo-epitopes: a novel approach.

Authors:  X Ai; B Butts; K Vora; W Li; C Tache-Talmadge; A Fridman; H Mehmet
Journal:  Cell Death Dis       Date:  2011-09-01       Impact factor: 8.469

4.  Untangling the Roles of Anti-Apoptosis in Regulating Programmed Cell Death using Humanized Yeast Cells.

Authors:  Caitlin Clapp; Liam Portt; Chamel Khoury; Sara Sheibani; Rawan Eid; Matthew Greenwood; Hojatollah Vali; Craig A Mandato; Michael T Greenwood
Journal:  Front Oncol       Date:  2012-06-13       Impact factor: 6.244

Review 5.  The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Authors:  Santiago Rello-Varona; David Herrero-Martín; Laura Lagares-Tena; Roser López-Alemany; Núria Mulet-Margalef; Juan Huertas-Martínez; Silvia Garcia-Monclús; Xavier García Del Muro; Cristina Muñoz-Pinedo; Oscar Martínez Tirado
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

6.  Targeted drug discovery for pediatric leukemia.

Authors:  Andrew D Napper; Venita G Watson
Journal:  Front Oncol       Date:  2013-07-08       Impact factor: 6.244

7.  C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice.

Authors:  Nirmal K Banda; Stephen Tomlinson; Robert I Scheinman; Nhu Ho; Joseline Ramos Ramirez; Gaurav Mehta; Guankui Wang; Vivian Pham Vu; Dmitri Simberg; Liudmila Kulik; V Michael Holers
Journal:  Front Immunol       Date:  2020-10-16       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.